Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 USD | +0.64% | -1.57% | -40.53% |
Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 | |
Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
Financials (USD)
Sales 2024 * | 9.01M | Sales 2025 * | 15.73M | Capitalization | 76.37M |
---|---|---|---|---|---|
Net income 2024 * | -57M | Net income 2025 * | -68M | EV / Sales 2024 * | 8.48 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.85 x |
P/E ratio 2024 * |
-1.52
x | P/E ratio 2025 * |
-1.56
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.03% |
Latest transcript on Cue Biopharma, Inc.
1 day | +0.64% | ||
1 week | -1.57% | ||
Current month | -16.93% | ||
1 month | -17.37% | ||
3 months | -44.72% | ||
6 months | -13.26% | ||
Current year | -40.53% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Anish Suri
PSD | President | 50 | 18-06-30 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 18-06-25 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Peter Kiener
BRD | Director/Board Member | 72 | 16-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +1.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 1.57 | +0.64% | 181,253 |
24-04-19 | 1.56 | -1.27% | 169,010 |
24-04-18 | 1.58 | -3.07% | 169,330 |
24-04-17 | 1.63 | +9.03% | 315,904 |
24-04-16 | 1.495 | -6.27% | 286,850 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.53% | 76.37M | |
+2.49% | 96.73B | |
-0.17% | 21.31B | |
-16.61% | 21.21B | |
-5.29% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- CUE Stock